Drug Classification and Mechanisms of Action in the Body
Drugs are classified by multiple systems—most commonly by anatomical site, therapeutic effect, chemical structure, and molecular mechanism—and they work in the body through specific pharmacokinetic processes (absorption, distribution, metabolism, excretion) and pharmacodynamic interactions with biological targets.
Primary Classification Systems
ATC Classification System
The World Health Organization established the Anatomical Therapeutic Chemical (ATC) system, which organizes drugs into five hierarchical levels 1:
- Level 1: Anatomical main group (where the drug acts)
- Level 2: Therapeutic subgroup (therapeutic application)
- Level 3: Pharmacological subgroup (pharmacological action)
- Level 4: Chemical subgroup (chemical properties)
- Level 5: Chemical substance (specific drug)
This system is updated annually by WHO experts in Oslo, Norway, based on new international generic names, scientific evidence, and international pharmacopeias 1.
Target-Based Classification (TCAT)
An alternative system classifies drugs by their molecular mechanism of action 2:
- Enzymes (inhibitors or activators)
- Substrates, metabolites, and proteins
- Receptors (agonists or antagonists)
- Ion channels (blockers or openers)
- Transporter molecules and systems
- Nucleic acids and ribosomes
- Physicochemical mechanisms
- Antigen-antibody reactions
- Unknown targets
Therapeutic Effect Classification
Drugs can also be categorized by their relationship to disease processes 3:
- Category 0: Prevent disease development when none exists
- Category I: Affect etiologic factors of disease
- Category II: Affect specific disease processes
- Category III: Affect specific disease manifestations
- Category IV: Affect non-specific symptoms
- Category V: Diagnostic or treatment-facilitating agents
How Drugs Work in the Body
Pharmacokinetic Processes
Absorption: Drugs are rapidly absorbed from the gastrointestinal tract, with effects typically beginning within 30 minutes of oral ingestion 4. Absorption rates vary by factors including gastric pH, gastric emptying, and food intake. Women show decreased gastric acid secretion and slower gastrointestinal transit, leading to delayed absorption of certain drugs like captopril, metoprolol, and verapamil 5.
Distribution: After absorption, drugs distribute throughout body compartments based on:
- Body composition: Lipophilic drugs (amiodarone, benzodiazepines, propranolol) have increased volume of distribution and longer half-lives in individuals with higher body fat 5
- Plasma protein binding: Highly protein-bound drugs (warfarin) can have altered free drug levels with changes in albumin or α1-acid glycoprotein 5
- Organ blood flow: Lower cardiac output and organ perfusion reduce drug delivery to target sites 5
Metabolism: The liver is the primary site of drug metabolism through two phases 5:
Phase I metabolism: Involves cytochrome P450 (CYP) enzymes, particularly CYP3A4, 2D6, 2C9, 2C19, and 1A2. Activity varies significantly between individuals—women show increased CYP3A4 and 2D6 activity but decreased CYP2C19 activity 5. Hormones (estrogens, oral contraceptives) and pregnancy alter enzyme activity 5.
Phase II metabolism: Conjugation reactions involving glucuronidation, sulfation, acetylation, and methylation make drugs more water-soluble for excretion 5.
Excretion: Kidneys eliminate most drugs and metabolites. Renal clearance depends on glomerular filtration rate (eGFR), tubular secretion, and reabsorption. Individuals with lower eGFR (women, elderly) have prolonged elimination half-lives for renally excreted drugs like ACE inhibitors, atenolol, bisoprolol, and digoxin 5.
Pharmacodynamic Mechanisms
Receptor Interactions: Many drugs work by binding to specific receptors:
- Stimulants (methylphenidate, amphetamines) bind to dopamine transporters in the striatum, increasing synaptic dopamine and enhancing prefrontal cortex executive function 4
- Beta-blockers block adrenergic receptors, reducing heart rate and blood pressure 6
- Opioids (meperidine, fentanyl) bind to opioid receptors throughout the central nervous system, producing analgesia and sedation 7
Enzyme Inhibition:
- Orlistat inhibits gastrointestinal lipases, decreasing fat absorption by approximately 30% 8
- ACE inhibitors block angiotensin-converting enzyme, reducing angiotensin II formation and lowering blood pressure 6
Transporter Modulation: Drugs affecting P-glycoprotein (P-gp) and other transporters alter drug exposure. Women have decreased P-gp activity, leading to increased exposure to substrates like digoxin, dabigatran, and diltiazem 5.
Critical Clinical Considerations
Drug-Drug Interactions
Pharmacokinetic interactions occur when one drug affects another's absorption, metabolism, distribution, or elimination. Verapamil and diltiazem are both CYP3A4 substrates and inhibitors, altering metabolism of other CYP3A4-processed medications 9.
Pharmacodynamic interactions occur when drugs affect each other's pharmacological response:
- Beneficial: RAS inhibitors with thiazide diuretics minimize hypokalemia; dihydropyridine calcium channel blockers with RAS inhibitors reduce lower extremity edema 9
- Adverse: Combining ACE inhibitors with ARBs increases hyperkalemia risk; meperidine with MAOIs causes life-threatening excitatory reactions with agitation, seizures, and hemodynamic instability 7, 9
Sex-Related Differences
Women experience more frequent and severe adverse drug reactions due to pharmacokinetic differences 5. Women with heart failure may require lower doses of ACE inhibitors, ARBs, and beta-blockers than men 5. Narrow therapeutic index drugs (digoxin) reach higher peak concentrations in women, producing more adverse effects 5.
Time Course of Drug Effects
Drug effects correlate with absorption phase rather than plasma half-life. Stimulants show "clockwise hysteresis"—effects disappear before the drug leaves plasma 4. Methylphenidate effects concentrate in the early absorption phase, with behavioral improvements beginning 30 minutes after ingestion and lasting 3-4 hours despite a 3-hour plasma half-life 4.
Common Pitfalls
- Assuming class effects: Not all drugs within a class are interchangeable. Beta-blockers differ in receptor selectivity, lipophilicity, and clinical outcomes 10
- Ignoring body weight/renal function: Failure to adjust doses for body weight or eGFR leads to drug accumulation and toxicity, particularly with renally excreted drugs 5
- Overlooking drug interactions: Always check for CYP3A4 interactions and avoid contraindicated combinations like MAOIs with meperidine or sympathomimetics 7, 9